Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509891 | 1.00 | EPHX2 (0.43) | EPHX2TSHRSMN1; SMN2TLR2TLR1 | |
| SCHEMBL1509858 | 0.97 | EPHX2 (0.43) | EPHX2TSHRSMN1; SMN2TLR2TLR1 | |
| SCHEMBL16538712 | 0.97 | EPHX2 (0.43) | EPHX2TSHRSMN1; SMN2TLR2TLR1 | |
| SCHEMBL1509898 | 0.97 | EPHX2 (0.43) | EPHX2TSHRSMN1; SMN2TLR2TLR1 | |
| SCHEMBL29680034 | 0.93 | TSHR (0.46) | EPHX2TSHRSMN1; SMN2TLR2TLR1 | |
| SCHEMBL1509850 | 0.91 | TLR2 (0.43) | EPHX2TSHRTLR2TLR1RECQL | |
| SCHEMBL1509876 | 0.91 | TLR2 (0.43) | EPHX2TSHRTLR2TLR1RECQL | |
| SCHEMBL15196457 | 0.90 | EPHX2 (0.43) | EPHX2TSHRSMN1; SMN2TLR2TLR1 | |
| SCHEMBL20556419 | 0.89 | EPHX2 (0.51) | EPHX2KDM4ERECQLGAAADRA1A | |
| SCHEMBL25530748 | 0.88 | GLP1R (0.44) | EPHX2TSHRSMN1; SMN2TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859493-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-10-14 | — | — | US | disclosed |
| US-8859493-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-10-14 | — | — | US | disclosed |
| EP-2292653-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2014-05-21 | — | — | EP | disclosed |
| EP-1846447-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-08-21 | — | — | EP | disclosed |
| US-20120208749-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-08-16 | — | — | US | disclosed |
| US-20120208749-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-08-16 | — | — | US | disclosed |
| EP-2292653-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| EP-1846447-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082205-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227796-A1 | Insulin Derivatives | IAPP, INSR, GCG | EPHX2 1255/4885TSHR 1325/4885SMN1; SMN2 4544/4885 |
| US-20120208749-A1 | Insulin derivatives | IAPP, INSR, GCG | EPHX2 1446/4885TSHR 1298/4885SMN1; SMN2 4611/4885 |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | EPHX2 2749/4885TSHR 2063/4885SMN1; SMN2 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.